This paper reports for the first time in the world a clinical study of using islet cell transplantation prepared from chemically reprogrammed induced pluripotent stem cells to treat type 1 diabetes.

This study constructed human pluripotent stem cell (hPSC)-derived vascularized macrophage-islet organoids (VMI organisms).

Mesenchymal stem cells are expected to provide a new treatment path for patients with type 2 diabetes.

TED-A9 is an investigational cell therapy designed to replace lost ventral midbrain specific dopaminergic cells in patients with Parkinson's disease.

The study's findings represent a major leap in understanding of multiple sclerosis and highlight the huge potential of glia as a target for therapeutic intervention, which may change the treatment prospects of many patients.

This article was published online on September 2 in the journal Nature cell biology by researchers at the University of Pompeii Fabra in Spain and ICREA Systems Bioengineering.

This world-first breakthrough could bring better personalized treatment to children with leukemia and bone marrow failure diseases.

The synthetic biology strategy developed in this study provides a promising solution to enhance the adhesion of xenogeneic cells and may help in the cultivation of human organs in animal models, thereby addressing the organ shortage crisis.